BioSpace News Archive

Longeveron Inc. today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.

Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.

BIOXYTRAN, INC. announced that the U.S Patent and Trademark Office has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food and Drug Administration’s Orange Book.

ReAlta Life Sciences, Inc. today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of RLS-0071 in patients with acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).

GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced an update on key strategic initiatives.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration, has joined its Scientific Advisory Board.

Therini Bio, Inc. , today announced interim results from the Phase 1 trial of its lead candidate, THN391, for the treatment of dementia.

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC) with resistance to certain targeted therapies.

Levita Magnetics, whose mission is to help more patients get access to better surgery, announced today the world’s first commercial use of its MARS™ platform.